Disease · MONDO_0005618

anxiety disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anxiety disorder. Diseases, record MONDO_0005618. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005618

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anxiety disorder; Open Targets
Open Targets ID: MONDO_0005618; Open Targets
Other names: anxiety disorders, anxiety neuroses, anxiety neurosis, anxiety/mood disorders, chronic stress, mood and anxiety disorder, mood and anxiety disorders, neurotic anxiety states; Open Targets
Disease Ontology: DOID:2030; Disease Ontology
MeSH: D001008; MeSH
NCI Thesaurus: C2878; NCI Thesaurus
Highest stage of its drugs: Approval, for 45 of its 137 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs137

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALPRAZOLAM	CHEMBL661	Small molecule	Approval	DailyMed, FDA and TTD	48	1	1	Drugs and targets
DULOXETINE	CHEMBL1175	Small molecule	Approval	EMA Human Drugs	6	1	1	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Approval	DailyMed and TTD	4	1	1	Drugs and targets
BUSPIRONE HYDROCHLORIDE	CHEMBL1200399	Small molecule	Approval	DailyMed and FDA	55	0	0	Drugs and targets
ESCITALOPRAM OXALATE	CHEMBL1200322	Small molecule	Approval	DailyMed	9	0	0	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Approval	EMA Human Drugs	9	0	0	Drugs and targets
DULOXETINE HYDROCHLORIDE	CHEMBL1200328	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
MEPROBAMATE	CHEMBL979	Small molecule	Approval	DailyMed and TTD	3	0	0	Drugs and targets
CHLORDIAZEPOXIDE	CHEMBL451	Small molecule	Approval	DailyMed and TTD	2	0	0	Drugs and targets

1 to 10 of 137

See all 137 drugs

Targets78

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA2	GABA-A receptor; anion channel	17	GABA receptor alpha-2 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	16	GABA receptor alpha-3 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	16	Serotonin transporter antagonist; Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
GABRA1	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA4	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	14	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 78

See all 78 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01302080	Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)		941	2021-10-08	Obsessive Compulsive Disorder	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT01928758	Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders	Not applicable	245	2019-02-08	Tobacco Dependence	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00233103	Treatment of Post-Traumatic Brain Injury (TBI) Depression	Phase 2	52	2015-11-13	Depression	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT01491035	Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder	Phase 2	48	2016-01-15	Depressive Disorder, Anxiety Disorder	VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00989937	Oxytocin Add-on Study for Stable Anxiety Patients	Not applicable	17	2019-09-25	Anxiety Disorders	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT05032807	Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation	Phase 1	14	2024-02-06	Absorption; Chemicals	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT01977729	Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline	Phase 2	1	2016-04-13	Anxiety Disorder of Adolescence	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00018057	Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders	Phase 2	3,500		Anxiety Disorders, Major Depressive Disorder	FLUOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00395213	Antidepressant Safety in Kids Study		569		Anxiety Disorders, Depressive Disorders, Eating Disorders, Obsessive Compulsive Disorder	CITALOPRAM, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE	Its record names the disease	ClinicalTrials.gov
NCT07164287	Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment		376		Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD), PTSD - Post Traumatic Stress Disorder	PSILOCYBIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: Abstinence From Smoking	17 of 94	4 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: deaths from any cause	0 of 94	0 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: serious adverse events	7 of 94	10 of 94	188	NCT01928758	Trial comparisons
Reduced Nicotine Content Cigarettes vs Usual Nicotine Content Cigarettes: Intention to Quit Smoking	33 of 69	25 of 74	143	NCT01928758	Trial comparisons
Sertraline vs Placebo: serious adverse events	0 of 22	0 of 19	41	NCT00233103	Trial comparisons
Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: deaths from any cause	0 of 14	0 of 14	28	NCT05032807	Trial comparisons
Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: serious adverse events	0 of 14	0 of 14	28	NCT05032807	Trial comparisons

Papers from its trials40

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39364684	RESULT	1	PubMed
18701066	RESULT	1	PubMed
42258278	DERIVED	1	PubMed
41241072	DERIVED	1	PubMed
39771516	DERIVED	1	PubMed
38355141	DERIVED	1	PubMed
38052059	DERIVED	1	PubMed
37730196	DERIVED	1	PubMed
36977629	DERIVED	1	PubMed
36905736	DERIVED	1	PubMed

1 to 10 of 40

See all 40 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005618

GET https://conductscience.org/api/diseases/v1/MONDO_0005618/drugs?page=2

API reference For AI assistants